CD274 and liver cancer: A full understanding of the TIME facilitates the development of new therapeutic targets, of which PD-1/PD-L1 is a relatively representative immune detection site, and in liver cancer, CMTM6 can stabilize PD-L1 and enhance the efficacy of immunotherapy (Liu et al., 2021).